Daily brief

Every weekday morning an AI co-pilot reads the overnight tape across the book, cross-references the catalyst calendar, and writes what moved and why.

• 2026-10-26A mixed, defensive pharma-supply session on Friday as the sterile-injectables rung and Eli Lilly slipped while bioprocessing held, with peptide-manufacturing small-cap Maravai edging the tape and Amphastar the standout decliner.
• 2026-10-23Pharma was the defensive winner of the day's rotation — the fill-finish and bioprocessing chokepoint caught a flight-to-safety bid led by Sartorius — while Corning, now effectively an AI-optical-fiber stock, fell 8% with the tech tape.
• 2026-10-22Charles River led the supply-chain basket on a wave of analyst upgrades tied to its investor-day plan, with Merck KGaA's bioprocessing ADR the laggard on an otherwise firm tape.
• 2026-10-21A broad healthcare bid lifted the CDMO and fill-finish names, with Charles River leading, while Baxter fell on an FDA warning letter at a sterile-injectables plant.
• 2026-10-20The bioprocessing and life-sciences-tools complex lagged the risk rebound as money rotated into semiconductors, with the peptide-manufacturing rung on both ends of the tape.
• 2026-10-19The bioprocessing and lab-tools rung sold off with the broader capex-sensitive risk-off while demand-inelastic generics and injectables caught a defensive bid.
• 2026-10-16The life-sciences tools and CDMO rungs rallied broadly on a risk-on session — Maravai +7.9% leading a high-beta bounce — with Corning the only meaningful laggard.
• 2026-10-15Pharma bucked the hot-CPI selloff as a defensive bid lifted large-cap drugmakers and bioprocessing tools — Eli Lilly +3.6%, Lonza and bioprocess names up 2-3% — while Corning's AI-optical exposure made it the laggard at -5.2%.
• 2026-10-14Maravai -7.5% led the nucleic-acid rung lower with the China CDMO names, while the bioprocessing-instrument chokepoint held — Mettler-Toledo +2.2%.
• 2026-10-13Pharma held as a risk-off haven — most fill-finish and injectables names green — while China's WuXi Biologics fell 7.4% and Corning's optics side dragged it down 6%.
• 2026-10-12A quiet, mostly-green pharma-supply tape — Repligen led the bioprocessing rung +6.1% — with the steepest decliner, Aptar, off just 1.2%.
• 2026-10-09Corning led a bioprocessing and CDMO pullback, off 6.4%, as AI-optics crosscurrents and China-exposure weighed on the group; primary-packaging name Aptar (+1.1%) was the rare gainer.
• 2026-10-08Large-cap drug demand anchors held bid while the bioprocessing and fill-finish chokepoint sold off — Eli Lilly up 2.7%, Maravai down 5.4% again.
• 2026-10-07Corning led the basket on a multibillion-dollar AT&T fiber deal unrelated to its pharma-glass franchise, while bioprocessing and life-science tools sold off with Maravai and Repligen hit hardest.
• 2026-10-06A life-science-tools rotation after Charles River's 2030 targets lifted the whole bioprocessing rung, with the glass-containment choke the lone laggard.
• 2026-10-05A quiet, tools-led pharma session — Maravai firmed on the oligo rung while the decliners stayed shallow.
• 2026-10-02A broad life-science-tools selloff dragged Repligen and the bioprocessing rung lower while packaging names held green.
• 2026-10-01A quiet pharma-supply tape as WuXi AppTec firmed on CDMO momentum under the BIOSECURE overhang and Amphastar drifted.
• 2026-09-30A quiet pharma-supply tape framed by two idiosyncratic moves — Corning's optical-driven rally and Fresenius's FDA-driven drop on a sterile-injectables warning.
• 2026-09-29Pharma-supply-chain names were a rare green corner as capital rotated into bioprocessing and analytical rungs, with Amphastar leading and optical-glass name Corning the laggard.
• 2026-09-28A quiet, defensive pharma-supply-chain session on Friday — Viatris firmed on its raised-guidance narrative while fill-finish name Stevanato slipped modestly.
• 2026-09-25Charles River's upbeat investor day lifted the bioprocessing and CRO rung while WuXi lagged under the BIOSECURE overhang.
• 2026-09-24A quiet, defensive pharma-supply tape — Amphastar's injectable rung led modestly while the GLP-1 anchor slid and Corning fell on a $2B raise.
• 2026-09-23Lab- and bioprocess-tools names led on a broad life-sciences bid while Amneal gave back its post-approval gains.
• 2026-09-22Amneal extended its complex-injectable rally to lead pharma-supply names, while Novo Nordisk sank 8% on a Capital Markets Day that disappointed on the obesity franchise.
• 2026-09-21A quiet, defensive pharma-supply tape let Amneal lead on an FDA complex-injectable approval, while fill-finish name Stevanato lagged.
• 2026-09-18Bioprocessing and tools firmed broadly, with small-cap mRNA-reagent name Maravai leading a low-conviction bounce and Baxter lagging.
• 2026-09-17Amneal led sterile-injectables names on a JPMorgan target raise while bioMerieux's OTC line lagged the QC-instruments rung.
• 2026-09-16Thermo Fisher led a conference-driven rally across the bioprocessing tools chokepoint, while finished-generics names lagged on a rate-heavy tape.
• 2026-09-15WuXi's ADR extended its 2026 rally on the CDMO chokepoint while Corning's $2B equity raise sank the pharma-glass name on dilution.